Lead Product(s): Daratumumab
Therapeutic Area: Oncology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Janssen Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2020
The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.